一、目标价上调与评级维持交银国际发布研报，将 荣昌生物 (09995)的目标价从109港元上调至112港元，并维持“买入”评级。这一调整基于公司核心产品的临床开发进展和未来商业化潜力。2026年将是公司的重要时间节点，重点关注泰它西普MG适应症和维迪西妥UC适应症的注册临床开发，以及RC28在DME获批和wAMD申报上市的进展。二、研发管线持续推进荣昌生物的研发管线展现出强劲动力。PD-1/...
Source Link一、目标价上调与评级维持交银国际发布研报，将 荣昌生物 (09995)的目标价从109港元上调至112港元，并维持“买入”评级。这一调整基于公司核心产品的临床开发进展和未来商业化潜力。2026年将是公司的重要时间节点，重点关注泰它西普MG适应症和维迪西妥UC适应症的注册临床开发，以及RC28在DME获批和wAMD申报上市的进展。二、研发管线持续推进荣昌生物的研发管线展现出强劲动力。PD-1/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.